244 related articles for article (PubMed ID: 15280845)
1. Systemic treatment of psoriatic patients with bexarotene decreases epidermal proliferation and parameters for inflammation, and improves differentiation in lesional skin.
Smit JV; de Jong EM; van Hooijdonk CA; Otero ME; Boezeman JB; van de Kerkhof PC
J Am Acad Dermatol; 2004 Aug; 51(2):257-64. PubMed ID: 15280845
[TBL] [Abstract][Full Text] [Related]
2. A phase II multicenter clinical trial of systemic bexarotene in psoriasis.
Smit JV; Franssen ME; de Jong EM; Lambert J; Roseeuw DI; De Weert J; Yocum RC; Stevens VJ; van De Kerkhof PC
J Am Acad Dermatol; 2004 Aug; 51(2):249-56. PubMed ID: 15280844
[TBL] [Abstract][Full Text] [Related]
3. A multiparameter flow cytometric analysis of the effect of bexarotene on the epidermis of the psoriatic lesion.
Franssen ME; Smit JV; Van Erp PE; Van De Kerkhof PC
Br J Dermatol; 2003 Sep; 149(3):506-12. PubMed ID: 14510982
[TBL] [Abstract][Full Text] [Related]
4. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma.
Duvic M; Martin AG; Kim Y; Olsen E; Wood GS; Crowley CA; Yocum RC;
Arch Dermatol; 2001 May; 137(5):581-93. PubMed ID: 11346336
[TBL] [Abstract][Full Text] [Related]
5. Plaque psoriasis vs. atopic dermatitis and lichen planus: a comparison for lesional T-cell subsets, epidermal proliferation and differentiation.
Bovenschen HJ; Seyger MM; Van de Kerkhof PC
Br J Dermatol; 2005 Jul; 153(1):72-8. PubMed ID: 16029329
[TBL] [Abstract][Full Text] [Related]
6. Assessment of epidermal subpopulations and proliferation in healthy skin, symptomless and lesional skin of spreading psoriasis.
Körver JE; van Duijnhoven MW; Pasch MC; van Erp PE; van de Kerkhof PC
Br J Dermatol; 2006 Oct; 155(4):688-94. PubMed ID: 16965416
[TBL] [Abstract][Full Text] [Related]
7. Pulsed dye laser versus treatment with calcipotriol/betamethasone dipropionate for localized refractory plaque psoriasis: effects on T-cell infiltration, epidermal proliferation and keratinization.
Bovenschen HJ; Erceg A; Van Vlijmen-Willems I; Van De Kerkhof PC; Seyger MM
J Dermatolog Treat; 2007; 18(1):32-9. PubMed ID: 17365265
[TBL] [Abstract][Full Text] [Related]
8. The changes in expression of ICAM-3, Ki-67, PCNA, and CD31 in psoriatic lesions before and after methotrexate treatment.
Yazici AC; Tursen U; Apa DD; Ikizoglu G; Api H; Baz K; Tasdelen B
Arch Dermatol Res; 2005 Dec; 297(6):249-55. PubMed ID: 16215763
[TBL] [Abstract][Full Text] [Related]
9. The effects of calcipotriol and methylprednisolone aseponate on bcl-2, p53 and ki-67 expression in psoriasis.
Adişen E; Gülekon A; Erdem O; Dursun A; Gürer MA
J Eur Acad Dermatol Venereol; 2006 May; 20(5):527-33. PubMed ID: 16684279
[TBL] [Abstract][Full Text] [Related]
10. Nature of cell kinetics in psoriatic epidermis.
Doger FK; Dikicioglu E; Ergin F; Unal E; Sendur N; Uslu M
J Cutan Pathol; 2007 Mar; 34(3):257-63. PubMed ID: 17302610
[TBL] [Abstract][Full Text] [Related]
11. Clinical and immunohistochemical evaluation of psoriatic plaques treated with topical 5-aminolaevulinic acid photodynamic therapy.
Fransson J; Ros AM
Photodermatol Photoimmunol Photomed; 2005 Dec; 21(6):326-32. PubMed ID: 16313245
[TBL] [Abstract][Full Text] [Related]
12. Negative regulation of two hyperproliferative keratinocyte differentiation markers by a retinoic acid receptor-specific retinoid: insight into the mechanism of retinoid action in psoriasis.
Nagpal S; Thacher SM; Patel S; Friant S; Malhotra M; Shafer J; Krasinski G; Asano AT; Teng M; Duvic M; Chandraratna RA
Cell Growth Differ; 1996 Dec; 7(12):1783-91. PubMed ID: 8959347
[TBL] [Abstract][Full Text] [Related]
13. Effects of narrowband UV-B on pharmacodynamic markers of response to therapy: an immunohistochemical study over sequential samples.
Carrascosa JM; Tapia G; Bielsa I; Fuente MJ; Ferrandiz C
J Cutan Pathol; 2007 Oct; 34(10):769-76. PubMed ID: 17880582
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma.
Kannangara AP; Levitan D; Fleischer AB
J Dermatolog Treat; 2009; 20(3):169-76. PubMed ID: 19016373
[TBL] [Abstract][Full Text] [Related]
15. Infliximab restores the balance between pro- and anti-apoptotic proteins in regressing psoriatic lesions.
Kokolakis G; Giannikaki E; Stathopoulos E; Avramidis G; Tosca AD; Krüger-Krasagakis S
Br J Dermatol; 2012 Mar; 166(3):491-7. PubMed ID: 21985184
[TBL] [Abstract][Full Text] [Related]
16. Clinical and immunohistochemical assessment of the effect of cyclosporin in keratinocytes and dermal dendrocytes in psoriasis.
Lago E; Carneiro S; Cuzzi T; Magalhães G; Cássia F; Pessanha F; Ramos-e-Silva M
J Cutan Pathol; 2007 Jan; 34(1):15-21. PubMed ID: 17214849
[TBL] [Abstract][Full Text] [Related]
17. The efficacy and safety of topically applied indigo naturalis ointment in patients with plaque-type psoriasis.
Lin YK; Wong WR; Chang YC; Chang CJ; Tsay PK; Chang SC; Pang JH
Dermatology; 2007; 214(2):155-61. PubMed ID: 17341866
[TBL] [Abstract][Full Text] [Related]
18. Selective persistence of dermal CD8+ T cells in lesional plaque psoriasis after clobetasol-17 propionate treatment.
Bovenschen HJ; Vissers WH; Seyger MM; van de Kerkhof PC
Acta Derm Venereol; 2005; 85(2):113-7. PubMed ID: 15823902
[TBL] [Abstract][Full Text] [Related]
19. Effects of oral bexarotene (targretin) on the minimal erythema dose for broadspectrum UVB light.
Smit JV; De Jong EM; Van De Kerkhof PC
Skin Pharmacol Appl Skin Physiol; 2003; 16(4):237-41. PubMed ID: 12784063
[TBL] [Abstract][Full Text] [Related]
20. Programmed cell death of keratinocytes in infliximab-treated plaque-type psoriasis.
Krüger-Krasagakis S; Galanopoulos VK; Giannikaki L; Stefanidou M; Tosca AD
Br J Dermatol; 2006 Mar; 154(3):460-6. PubMed ID: 16445776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
